|Articles|September 7, 2022
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
Advertisement
IQVIA announced new evidence that decentralized clinical trials (DCTs) deliver measurable benefits for patients, sites, and sponsors.
In this analysis decentralized trials were assessed against 14 metrics across three categories—productivity, quality, and trial delivery, to determine how a DCT approach compared to traditional study models. The analysis found that sponsors can achieve faster, less expensive, and more engaging trials using DCT driven protocols.
Read more about the study
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data
2
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
3
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
4
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
5